Phase 2 Leukaemia Trial, Recruiting (NCT00801489)

Phase 2 Leukaemia Trial, Recruiting NCT00801489 Sponsor: M.D. Anderson Cancer Center Condition: Leukaemia

Printed from Voxsanity (voxsanity.com.au) — NCT00801489 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Leukaemia

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with untreated AML (a type of blood cancer) or a high-risk blood disorder called MDS, and your cancer cells have one of these specific genetic changes: t(8;21), inv(16), or t(16;16)
You are willing and able to sign a written consent form to take part in the study
You may still be considered even if you are not in the best physical health — if you are quite unwell, the study team will discuss the right treatment schedule with you
You may still be considered even if you have problems with certain organs, such as your kidneys, heart, or liver — the team will adjust your doses as needed
You have had up to one previous round of treatment to try to put your cancer into remission, if your specific genetic changes were not spotted at first
If you could become pregnant, you must be willing to use effective birth control during the trial

Who may not be able to join:

You are currently pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Gautam Borthakur, M.D. Anderson Cancer Center

Phone: 713-563-1586

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT00801489

Sponsor: M.D. Anderson Cancer Center

Phase: Phase 2

Status: Recruiting

Condition: Leukaemia

Trial contact: 713-563-1586

More information: https://clinicaltrials.gov/study/NCT00801489

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with untreated AML (a type of blood cancer) or a high-risk blood disorder called MDS, and your cancer cells have one of these specific genetic changes: t(8;21), inv(16), or t(16;16)
You are willing and able to sign a written consent form to take part in the study
You may still be considered even if you are not in the best physical health — if you are quite unwell, the study team will discuss the right treatment schedule with you
You may still be considered even if you have problems with certain organs, such as your kidneys, heart, or liver — the team will adjust your doses as needed
You have had up to one previous round of treatment to try to put your cancer into remission, if your specific genetic changes were not spotted at first
If you could become pregnant, you must be willing to use effective birth control during the trial

Who may not be able to join:

You are currently pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

M.D. Anderson Cancer Center

Registry

ClinicalTrials.gov

Start date

4 April 2007

Est. completion

11 October 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Complete remission rate; Toxicity rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov